In the second quarter of 2009, Lilly reported a worldwide total revenue of $5292.8m, an increase of 3% compared with $5,150.4m for the second quarter of 2008. Net income reported for the Q2 was $1158.5m, an increase of 21%, compared to $958.8m for the same period, 2008. EPS showed an increase of 20% from 0.88 to 1.06.
John Lechleiter, chairman and chief executive officer of Lilly, said: Lilly continues to deliver solid financial results notwithstanding the challenging global economic environment. Our business remained strong in the second quarter, with volume-driven revenue growth, good operating leverage and double-digit EPS growth. Sales of Cymbalta and Alimta were particularly noteworthy this quarter, while movements in foreign exchange rates led to an improved gross margin percent.
“In addition, we continued to advance molecules into and through our pipeline, and now have 66 molecules in clinical development. We also received several important regulatory approvals, most notably Effient in the U.S. Based on these results, and our outlook for the remainder of the year, we have raised our full-year 2009 pro forma non-GAAP earnings per share guidance.